MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
21 Abril 2021 - 9:00AM
Business Wire
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision
support tools and services for the global investment community,
announced today its collaboration with Royalty Pharma plc (Nasdaq:
RPRX), the largest buyer of biopharmaceutical royalties and a
leading funder of innovation across the biopharmaceutical industry,
to expand MSCI’s thematic index suite with the launch of new
indexes that aim to capture long-term, cutting edge themes that
will disrupt the life sciences, biotechnology and pharmaceutical
industry groups.
The initial indexes will measure the performance of companies
focused on delivering new and innovative therapeutic treatments
related to virology and oncology. Royalty Pharma will provide
expertise on various medical conditions, clinical trials,
transformative therapies and technologies that may lead to
breakthrough medical treatments that will assist MSCI to design a
classification framework and index methodologies.
Henry Fernandez, Chairman and Chief Executive Officer of
MSCI, said: “The Covid-19 pandemic has had a profound impact on
all aspects of society and has proven to be an accelerant for
long-term, structural changes, particularly in the life sciences.
As we have seen during this time, life sciences companies are
pivotal to shaping and advancing the healthcare industry and have
been critical to the development of approaches for prevention and
treatment of diseases. MSCI is thrilled to partner with Royalty
Pharma to design thematic indexes that capture companies at the
forefront of this evolving landscape and having a positive impact
on the future of our world.”
Pablo Legorreta, Founder and Chief Executive Officer of
Royalty Pharma, stated: “As a leading funder of innovation in
life sciences, we are extremely excited to collaborate with MSCI to
develop innovative index solutions that will be licensed as the
basis for indexed financial products such as ETFs targeting this
dynamic sector. This collaboration leverages Royalty Pharma’s deep
clinical and scientific knowledge built over decades, as well as
the unique capabilities of our Strategy and Analytics team. This
venture represents another example of Royalty Pharma’s creative
approach to monetizing its existing intellectual capital through
the creation of indexes that support investment in life
sciences.”
The indexes are planned to launch later this year.
For more information, please visit
msci.com/thematic-investing.
About MSCI Inc.
MSCI is a leading provider of critical decision support tools
and services for the global investment community. With over 50
years of expertise in research, data and technology, we power
better investment decisions by enabling clients to understand and
analyze key drivers of risk and return and confidently build more
effective portfolios. We create industry-leading research-enhanced
solutions that clients use to gain insight into and improve
transparency across the investment process.
The information contained herein (the “Information”) may not be
reproduced or redisseminated in whole or in part without prior
written permission from MSCI. The Information may not be used to
verify or correct other data, to create any derivative works, to
create indexes, risk models, or analytics, or in connection with
issuing, offering, sponsoring, managing or marketing any
securities, portfolios, financial products or other investment
vehicles. Historical data and analysis should not be taken as an
indication or guarantee of any future performance, analysis,
forecast or prediction. None of the Information or MSCI index or
other product or service constitutes an offer to buy or sell, or a
promotion or recommendation of, any security, financial instrument
or product or trading strategy. Further, none of the Information or
any MSCI index is intended to constitute investment advice or a
recommendation to make (or refrain from making) any kind of
investment decision and may not be relied on as such. The
Information is provided “as is” and the user of the Information
assumes the entire risk of any use it may make or permit to be made
of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR
ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY
INVOLVED IN MAKING OR COMPILING THE INFORMATION (EACH, AN
“INFORMATION PROVIDER”) MAKES ANY WARRANTIES OR REPRESENTATIONS
AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION
PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES,
INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE FOREGOING AND TO
THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE
INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE
INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE,
CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF
NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall
not exclude or limit any liability that may not by applicable law
be excluded or limited.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210421005577/en/
Media Inquiries PR@msci.com Sam Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049 Laura Hudson + 44 207 336 9653
Rachel Lai +852 2844 9315
Investor Inquiries sallilyn.schwartz@msci.com Salli Schwartz +1 212
804 5306
MSCI Global Client Services EMEA Client Service + 44 20
7618.2222 Americas Client Service +1 888 588 4567 (toll free) Asia
Pacific Client Service + 852 2844 9333
MSCI (NYSE:MSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
MSCI (NYSE:MSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024